ASCO 2018 | Results from CAR T-cell bb2121 first-in-human trial for R/R MM
Noopur Raje
• 1 Jun 2018
The anti-BCMA CAR T-cell therapy bb2121 looks extremely promising in multiple myeloma (MM). Here, Noopur Raje, MD, of Massachusetts General Hospital Cancer Center, Boston, MA, discusses the results of CRB-401 (NCT02658929), a first-in-human trial of bb2121 in relapsed/refractory MM, which were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL. Prof. Raje also highlights avenues for further study and the key questions that remain to be answered.
